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liver disease. Literature review was performed to obtain other
probabilities for the model. The effectiveness measure was the
number of patients immune to both HAV and HBV. RESULTS:
The selective strategy was less costly but less effective with a 
cost-effectiveness ratio of $105 per patient immune to HAV&
HBV. The universal strategy was more effective but more 
expensive with a cost-effectiveness ratio of $112 per patient
immune to HAV& HBV. Compared with the selective strategy,
universal strategy was associated with an incremental cost-
effectiveness (ICE) ratio of $154 per additional patient immune
to HAV and HBV. The universal strategy would become more
cost-effective if the cost of combined vaccine reduces by >9.7%
to <$0.75, if the cost of HBV vaccine increases by >25% to
>$34.50, if the cost of blood tests for immunity increases by
>23% to >$25.25, or if the prevalence of anti-HBs decreases 
to <24%. CONCLUSIONS: The selective vaccination strategy
for HAV and HBV in our sample of patients with HCV is more
cost-effective. However, the ICE for the universal strategy is
minimal.
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Peginterferon alfa-2a (40KD) (PEGASYS®), a new treatment
option for patients infected with chronic hepatitis B (CHB),
offers improved efﬁcacy with a deﬁned treatment duration 
compared with lamivudine (LAM), but at a higher cost. 
OBJECTIVE: To assess the clinical outcomes, costs and cost-
effectiveness of PEGASYS for the treatment of patients with
HBeAg-negative CHB, compared to LAM treatment for one-year
and four-years. METHODS: A cost-effectiveness analysis from
the UK National Health Service (NHS) perspective using a state-
transition Markov model simulating the natural history of
HBeAg-negative CHB. Efﬁcacy data were obtained from a
recent, randomized clinical trial comparing PEGASYS and LMV
in patients with HBeAg-negative CHB. Patients: Hypothetical
cohort of 40-year old patients with HBeAg-negative CHB. Inter-
ventions: PEGASYS and LAM monotherapy. Measurements: Life
expectancy, quality-adjusted life expectancy, lifetime costs, and
incremental cost-effectiveness ratios (ICERs). RESULTS: Forty-
eight week treatment with PEGASYS compared to LAM resulted
in higher total costs, but greater quality-adjusted life expectancy,
yielding an ICER of £5047/quality-adjusted life year (QALY)
gained. Although there is uncertainty associated with the prog-
nosis of HBeAg-negative CHB, the ICER did not exceed
£10,000/QALY gained despite variation in each parameter used
in the analysis. In the analysis comparing 48-week treatment
with PEGASYS to 208-week treatment with LAM, the ICER was
£2767/QALY gained. CONCLUSIONS: Short-term treatment
with PEGASYS compared to either short-term or long-term
LAM treatment in CHB patients who are HBeAg-negative
appears to offer life expectancy beneﬁts at a cost-effectiveness
ratio comparable to other currently reimbursed pharmaceutical
interventions.
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OBJECTIVE: Evaluate utilization and expenditure for treatment
of gastrointestinal infection with Helicobacter pylori (H. pylori)
by different durations of treatment. METHODS: Retrospective
analysis of pharmacy and outpatient procedure claims between
January 1, 2000 and December 31, 2002 in the MarketScan®
Commercial Claims and Encounters, Medicare Coordination of
Beneﬁts, and January 1, 1999 and December 31, 2001 in Multi-
State Medicaid databases. Patients were required to have one
claim for any proton pump inhibitor (esomeprazole, lansopra-
zole, omeprazole, pantoprazole, rabeprazole) and an antibiotic
combination of amoxicillin/clarithromycin (AC) or metronida-
zole/tetracycline (MT). Treatment patterns were evaluated along
with re-treatment rates (regimen effectiveness), testing rates, and
pharmaceutical expenditures. RESULTS: In total, 10,203
patients were identiﬁed; the average patient age was 52.8 years,
the majority of patients were female, 41.6% had privately
funded insurance and 58.4% had publicly funded insurance. The
majority of patients were naïve to H. pylori eradication therapy
over the 12 months prior to initial therapy and 92.6% of patients
received AC as their antibiotic combination. Fourteen-day triple
therapy (PPI + two antibiotics) was prescribed for majority
(80%) of patients regardless of H. pylori eradication therapy
treatment history. Re-treatment rates did not vary signiﬁcantly
among different triple therapy treatment regimen durations:
7.8% for seven day, 7.6% for ten day, and 7.9% for 14 day reg-
imens. However, the cost of initial treatment for the different
treatment durations varied widely, $120.82 for seven day regi-
mens, $178.79 for ten day regimens, and $294.49 for 14 day
regimens. CONCLUSION: This study found signiﬁcant differ-
ences in treatment costs by duration of therapy despite similar
re-treatment rates among different lengths (seven day vs. 14 day)
of H. pylori triple therapy regimens. There are potential eco-
nomic beneﬁts realized in shorter duration of treatment, as mea-
sured by the direct expenditures on the medications themselves,
and associated re-treatment and testing expenditures.
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OBJECTIVE: Crohn’s disease (aka: inﬂammatory bowel disease,
regional enteritis) is a chronic autoimmune disorder that can
occur at any age. This analysis examined use and cost of hospi-
talizations, observation unit (OU) stays and emergency depart-
ment (ED) visits during a one-year period by patients with
Crohn’s disease. METHODS: Using 2001–2002 Massachusetts
ED, OU and inpatient data, a cohort was identiﬁed by personal
identiﬁers and ICD-9 principal diagnosis codes (555.0–555.9).
An encounter proﬁle was established for each patient starting
with the ﬁrst stay or visit at any hospital, ED or OU in Massa-
chusetts in 2001. From that index encounter, each contact for
regional enteritis was tracked for 12 months for that patient.
Cost estimates, reported in 2004 USD, include accommodations
and ancillary services. Charges were adjusted using a 0.55 cost-
to-charge ratio and appropriate inﬂation indices. RESULTS: A
